An overview of the regulatory information required for a clinical trial /marketing authorisation application using a theoretical biotechnological protein product: A Pegylated Monoclonal Antibody.
Regulatory requirements for Biotechnological Products Part I
Previous
Previous
Regulatory Requirements for Biotechnological Products - Good Tissue Practice
Next
Next